Implantica Wins FDA Approval For RefluxStop, Eight Years After European Launch

Implantica has won FDA approval for RefluxStop, giving the medtech access to the U.S. gastroesophageal reflux disease market after the implant had already been available in Europe since August 2018.

The company describes RefluxStop as an implant placed on the upper part of the stomach through keyhole surgery, designed to help reduce or stop acid from entering the oesophagus without the need for long-term medication. For a company entering a market it estimates includes around 78 million GERD patients in the U.S., the approval matters, but the commercial signal in Implantica’s own announcement was measured rather than immediate-scale.

The Commercial Picture

The device went through the FDA’s Premarket Approval process, which the source describes as requiring extensive five-year clinical data to prove long-term safety and effectiveness. That gives Implantica a higher-regulatory-bar entry point into the U.S., but it does not remove the main adoption constraint for surgical devices: building enough trained physicians and activated sites.

Implantica said the initial rollout will be targeted at selected leading U.S. centers and reflux surgeons. CEO and founder Dr. Peter Forsell said commercial adoption is expected to build gradually because physician training and site activation are required to establish RefluxStop at each center. That makes this approval more of an infrastructure build than a broad launch event.

An implant also sits in a narrower treatment slot than medicines such as PPIs or diet changes and restrictions, which many GERD patients already use. The company’s pitch is therefore aimed at patients who do not want or cannot tolerate current drugs, not at replacing first-line treatment across the full market.

The Road Here

RefluxStop has been on the European market for eight years and, according to Implantica, has been used to treat 1,800 patients across more than 60 Centers of Excellence. The company also said in a financial update after the FDA approval that sales have increased by more than 60% compared with the prior-year period, reflecting continued commercial growth across key European markets.

Implantica said it will now expand its U.S. organization and work on logistics and distribution infrastructure. The broader industry takeaway is that FDA approval gives RefluxStop permission to compete, but the pace of U.S. uptake is likely to depend less on novelty than on whether Implantica can replicate a trained-center model at commercial scale.